SBIR PHASE II: Marker Gene Directed Substrates for Cell Regulation

SBIR 阶段 II：用于细胞调节的标记基因定向底物

• 批准号: 9710722
• 负责人: John Naleway
• 金额: $ 29.89万
• 依托单位: MARKER GENE TECHNOLOGIES, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-11-01 至 2000-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9710722&HistoricalAwards=false
• 关键词: SBIR; PHASE; II; Marker; Gene

*** 9710722 Naleway This Small Business Innovation Research Phase II project aims to develop new commercial uses of conjugates capable of exploiting common marker gene expression in transformed cells to control the growth and character of cells in living tissue. From our successes in Phase I we propose research that will provide breakthroughs needed to advance commercial uses of these recombinant gene systems in biotechnology. In Phase II of this project, Marker Gene Technologies, Inc. proposes to establish this technology by preparing new conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to a variety of animal cells or bacteria in tissue culture that contain gene fusion marker genes. In addition, Marker Gene Technologies, Inc. will develop new vectors and systems for defined control of marker genes in vivo. These new conjugate systems will provide innovative methods of detecting gene fusions and utilizing these fusion systems in transformed cells in vivo to control selected biological properties of these cells. Potential Commercial Applications of the Research The success of this project opens up commercial possibilities in the fields of medical intervention in genetic diseases, new drug delivery systems, and improved biotechnological production of new proteins and drugs in cell-culture systems. ***

* 9710722 Naleway 这个小型企业创新研究第二阶段项目旨在开发能够利用转化细胞中常见标记基因表达的缀合物的新商业用途，以控制活组织中细胞的生长和特征。 从我们在第一阶段的成功，我们提出的研究，将提供必要的突破，以推动这些重组基因系统在生物技术中的商业用途。 在该项目的第二阶段，Marker Gene Technologies，Inc.提出了通过制备常见生长调节剂、药物和酶抑制剂的新缀合物来建立该技术，用于施用到组织培养物中的含有基因融合标记基因的各种动物细胞或细菌。 此外，Marker Gene Technologies，Inc.将开发新的载体和系统，用于体内标记基因的确定控制。 这些新的缀合物系统将提供检测基因融合和在体内转化细胞中利用这些融合系统以控制这些细胞的选定生物学特性的创新方法。 研究的潜在商业应用 这一项目的成功为遗传疾病的医疗干预、新的药物输送系统以及改进细胞培养系统中新蛋白质和药物的生物技术生产等领域开辟了商业可能性。 ***